IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own0.10% Shs Outstand253.26M Perf Week-0.99%
Market Cap775.03M Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float219.58M Perf Month-32.73%
Income-129.40M PEG- EPS next Q-0.21 Inst Own88.30% Short Float7.72% Perf Quarter-37.52%
Sales92.20M P/S8.41 EPS this Y-168.30% Inst Trans1.45% Short Ratio4.21 Perf Half Y-39.46%
Book/sh1.21 P/B2.90 EPS next Y-26.50% ROA-32.20% Target Price12.00 Perf Year-46.73%
Cash/sh1.98 P/C1.77 EPS next 5Y- ROE-66.60% 52W Range3.46 - 7.77 Perf YTD-52.76%
Dividend- P/FCF- EPS past 5Y5.70% ROI-38.40% 52W High-54.89% Beta1.22
Dividend %- Quick Ratio5.40 Sales past 5Y26.60% Gross Margin- 52W Low1.30% ATR0.34
Employees106 Current Ratio5.40 Sales Q/Q142.70% Oper. Margin- RSI (14)31.01 Volatility7.80% 7.84%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin- Rel Volume1.14 Prev Close3.95
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume4.02M Price3.51
Recom1.90 SMA20-23.39% SMA50-28.08% SMA200-38.35% Volume4,591,478 Change-11.27%
Mar-21-22Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $6
Feb-11-22Initiated BMO Capital Markets Outperform $18
Dec-01-21Upgrade Jefferies Hold → Buy $7 → $12
Oct-26-20Resumed H.C. Wainwright Buy $11
Oct-02-20Upgrade Guggenheim Neutral → Buy $14
Sep-29-20Resumed JP Morgan Neutral
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
May-10-22 04:30PM  
May-06-22 01:30PM  
07:45AM  
06:30AM  
May-03-22 08:55AM  
May-02-22 04:30PM  
Apr-28-22 11:18AM  
Apr-21-22 04:01PM  
Apr-01-22 04:30PM  
11:23AM  
Mar-31-22 04:30PM  
Mar-30-22 11:51AM  
Mar-29-22 06:30AM  
Mar-21-22 03:07PM  
03:00PM  
08:26AM  
Mar-19-22 07:15PM  
Mar-10-22 06:30AM  
Mar-01-22 04:30PM  
Feb-28-22 10:20AM  
Feb-27-22 09:16PM  
07:48AM  
Feb-25-22 07:45AM  
06:30AM  
Feb-23-22 04:30PM  
Feb-16-22 10:58AM  
10:46AM  
Feb-15-22 11:19AM  
06:40AM  
06:30AM  
Feb-10-22 04:01PM  
Feb-08-22 08:55AM  
Feb-04-22 04:30PM  
03:00PM  
Feb-01-22 04:30PM  
Jan-31-22 06:30AM  
Jan-06-22 04:34PM  
Jan-05-22 01:38PM  
Jan-04-22 10:00AM  
Jan-03-22 10:36PM  
04:30PM  
Dec-31-21 06:44AM  
Dec-29-21 04:30PM  
Dec-14-21 09:01AM  
Dec-12-21 09:30AM  
Dec-11-21 10:19PM  
06:00AM  
Dec-06-21 04:01PM  
Dec-02-21 12:00AM  
Dec-01-21 01:25PM  
10:06AM  
09:22AM  
Nov-30-21 04:33PM  
04:01PM  
12:48PM  
08:15AM  
06:30AM  
05:55AM  
02:11AM  
Nov-24-21 04:30PM  
Nov-17-21 04:01PM  
Nov-16-21 04:30PM  
06:30AM  
Nov-11-21 10:58AM  
Nov-04-21 09:00AM  
Nov-01-21 08:03PM  
04:04PM  
12:24PM  
09:11AM  
Oct-29-21 05:00PM  
07:45AM  
06:30AM  
Oct-22-21 03:00PM  
Oct-19-21 12:31PM  
Oct-14-21 04:01PM  
Oct-01-21 04:30PM  
Sep-22-21 04:01PM  
Aug-02-21 04:30PM  
09:19AM  
Jul-30-21 11:30AM  
07:55AM  
06:30AM  
Jul-23-21 03:00PM  
Jul-15-21 04:01PM  
Jul-13-21 08:38AM  
Jul-01-21 04:30PM  
Jun-10-21 02:09AM  
Jun-09-21 11:30AM  
Jun-01-21 04:30PM  
May-20-21 04:30PM  
May-19-21 05:00PM  
May-10-21 12:00PM  
11:03AM  
07:45AM  
06:30AM  
06:15AM  
May-03-21 04:30PM  
Apr-26-21 04:01PM  
Apr-20-21 10:13AM  
Apr-16-21 04:41AM  
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL DEAN JDirectorSep 03Option Exercise3.8783,000321,40093,000Sep 03 04:06 PM